Financial statement for the first nine months of 1995.

NEW YORK--(BUSINESS WIRE)--November 8, 1995--

-- Consolidated sales increased by 3% to DKK 10,275 million - despite a decline in Novo Nordisk's invoicing currencies of more than 5% and divestiture of certain business activities, including Ferrosan A/S.

- Health Care Business sales up 9%.

- Enzyme Business sales down 2%.

-- Provision of approximately DKK 200 million for possible costs and write-offs in connection with divestitures or discontinuation of business activities.

-- Operating income increased by 14% to DKK 1,576 million.

-- Positive developme...

If you are already a vLex customer, Access Here